“Only through striving can we achieve constant renewal” — Upholding core principles while forging ahead, innovation remains at the forefront! Our 34th invention patent has been approved!
Good news alert! Leading Medical has earned another prestigious technological accolade!
Recently, Leading Medical “A monoclonal antibody against CK-MB and its applications” The invention patent has been officially approved, marking another significant achievement for Liding. Invention Patent No. 34 !
In the field of CK-MB assay, currently available reagents commonly suffer from mismatches in antibody affinity and significant cross-reactivity interference, resulting in inadequate assay specificity and a high risk of false‑positive or false‑negative results.
To this end, Leading Medical has developed a CK-MB monoclonal antibody pair that can be used in the preparation of reagents for latex immunoturbidimetry, immunochromatography, and other assays. By screening optimal antibody pairs and optimizing the buffer system, cross‑interference is effectively minimized, while assay sensitivity and specificity are enhanced.

This time approved CK-MB monoclonal antibody pair Related technologies will further refine the core reagent system in the in vitro diagnostics field, thereby… Myocardial injury and related diseases Its precise detection provides a more robust technological foundation, helping to enhance the efficiency and accuracy of clinical diagnosis and safeguarding the health and well-being of more people.
Leading Biochemical Immunoassay Reagents – Myocardial Injury Detection Series
Test Items
|
English abbreviation
|
Reagent ratio
|
Item number
|
Detection method
|
Creatine kinase isoenzyme
|
CK-MB
|
R1:R2=4:1
|
LD-CKMB-01
|
Inhibition method
|
Creatine kinase isoenzyme
|
CK-MB
|
R1:R2=3:1
|
LD-CKMB-02
|
Latex-enhanced immunoturbidimetric assay
|
Creatine kinase
|
CK
|
R1:R2=4:1
|
LD-CK-01
|
Rate method
|
Alpha-hydroxybutyrate dehydrogenase
|
HBDH
|
R1:R2=4:1
|
LD-HBDH-01
|
Rate method
|
Ischemia-modified albumin
|
IMA
|
R1:R2=3:1
|
LD-IMA-01
|
Free cobalt colorimetric method
|
Myoglobin
|
Mb
|
R1:R2=3:1
|
LD-Mb-01
|
Latex-enhanced immunoturbidimetric assay
|
Lactate dehydrogenase
|
LDH
|
R1:R2=4:1
|
LD-LDH-01
|
Rate method
|
Lactate dehydrogenase isoenzyme 1
|
LDH1
|
R1:R2=4:1
|
LD-LDH-01
|
Chemical Inhibition–Lactic Acid Substrate Method
|
Cardiac Troponin I
|
cTnI
|
R1:R2=4:1
|
LD-cTnI-01
|
Latex-enhanced immunoturbidimetric assay
|
Endless wisdom, a river of innovation through patent aggregation.
As a pioneer of innovation in the in vitro diagnostics industry, Leading Medical has consistently remained committed to technological breakthroughs, steadily advancing on the path of precision medicine. To date, the company has cumulatively submitted… 81 patent applications , among which 48 invention patents , already have 34 invention patents have been successfully granted. Behind every patent lies the unwavering dedication of our R&D team, as well as a steadfast commitment to harnessing innovation to advance healthcare.
Innovation knows no bounds, and progress never stops.
Looking ahead, Leading Medical will remain committed to the philosophy of “upholding fundamentals while striving for excellence,” continuously ramping up R&D investment, overcoming more technical challenges, and strengthening its competitive edge with a steady stream of high‑quality innovations, thereby injecting sustained momentum into the development of the in‑vitro diagnostics industry.
2022-07-26
xy13584019024